Background {#Sec1}
==========

Parasitic diseases are the main challenge of livestock production in the world. They cause huge losses by inducing high morbidity and mortality. Hence, livestock producers use anthelmintic drugs to control helminthic parasites. Several anthelmintic drugs are available in the market. Albendazole is the most commonly used anthelmintic drug in Ethiopia \[[@CR1]--[@CR3]\]. It is used for the treatment of variety of parasitic worms due to its broad spectrums of activities \[[@CR2]\]. To be effective in treating parasitic diseases, the drug should have the necessary physical and chemical qualities \[[@CR4], [@CR5]\].

Albendazole imported by private companies takes the largest share in Ethiopian market, in a limited extent the drug is also produced domestically. The quality of veterinary drugs imported, manufactured and distributed in the country is controlled by Ethiopian Veterinary Drug and Feed Control and Administration Authority. The authority has checkpoints at potential entry sites. However, there may be importation and distribution of substandard drugs \[[@CR3], [@CR6]\]. There are also complaints from animal health professionals and animal owners regarding the effectiveness of available drugs in the market \[[@CR2]\]. Many stakeholders in the animal health sector have concerns about treatment failures \[[@CR7]\].

Studies in other part of the world showed the possibility of counterfeiting on both branded and generic products \[[@CR8], [@CR9]\]. It has been reported that drugs on the market can have the correct ingredients, insufficient quantity of the active ingredient, wrong ingredients, no active ingredients or false or misleading packaging. They may also contain different quantities of impurities that can be harmless or toxic \[[@CR10], [@CR11]\].

Several studies have been conducted on the efficacy of albendazole using in vivo or in vitro techniques in Ethiopia and reported good or low efficacy \[[@CR1], [@CR3], [@CR12]\]*.* The low efficacy reports may be related either to the development of drug resistance by parasites or the quality of the preparation. This necessitated further investigation and comparison with standard products. There was no attempt in the country so far to assess the quality of albendazole tablets legally circulating in the market. Therefore, this study was designed to evaluate the quality of different brands and batches of albendazole tablets sold in the legal pharmaceutical markets in Addis Ababa, Ethiopia.

Methods {#Sec2}
=======

This study was conducted from November, 2016 to April, 2017 in Addis Ababa city which is the capital city of Ethiopia. The city acts as a hub for distribution of veterinary pharmaceuticals in the country. All tests were conducted in the National Animal Products, Veterinary Drug and Feed Quality Assessment Centre. Ten batches of albendazole tablets from six different brands with three different labelled dose (strength) (300, 600 and 2500 mg per tablet) of albendazole were collected randomly from different legal veterinary pharmacies in the city.

Samples were evaluated for various physical characteristics, packing information, label and information insert (leaflet), and weight. For weight evaluation, twenty tablets from each batch were weighed individually and compared \[[@CR13]\].

For the identification test, FTIR, UVS and HPLC were used. In the FTIR approach, approximately 200 mg of pure KBr crystal was taken and finely crushed by mortar and pestle. Then 2% of the powdered albendazole was added. The two powders were thoroughly mixed together and using oil pressure rotary pump a disk was formed. Another disk of KBr without albendazole was also prepared. Then both disks were placed on the sample handler and inserted into the instrument \[[@CR13]\].

In the UVS spectrometric test, a portion of a clear solution of both sample and standard were taken separately. These solutions were diluted with acidified methanol to obtain solutions containing 10 μg of albendazole per mL. Then, the test and the standard solutions were examined spectrophotometrically over the spectral range from 200 to 400 nm \[[@CR12]\].

HPLC equipped with an ultraviolet-visible detector (SPD-20A/20AV, Shimadzu Corporation, Japan) was used for qualitative and quantitative evaluation. HPLC grade solvents and albendazole 200 mg standard (USP-CRM, USA) were used. In HPLC system, we used a 254 nm detection wave length and a 4.6 mm × 25 cm column type that contains 5 μparticle sizes. According to USP \[[@CR13]\], the flow rate was one mL per minute. The total chromatography run time was 12 min. The mobile phase in HPLC machine was prepared by dissolving 0.5 g of monobasic ammonium phosphate in 400 mL of deionized HPLC grade water and 600 mL methanol. The sample was prepared by transferring 100 mg of finely powdered tablets of albendazole into a 50 mL volumetric flask. Then, 5 mL of diluent was added, sonicated for 30 min, diluted with methanol to volume, mixed thoroughly and filtered using Whatman filter paper. The first 15 mL of the filtrate was discarded and then 5 mL of the clear stock filtrate was transferred into the second volumetric flask and diluted with methanol to obtain a solution containing 200 μg of albendazole per mL \[[@CR13]\]. The standards were prepared based on the direction in USP \[[@CR13]\]. Prepared solutions were passed through 0.45 μm syringe filter and transferred into 1.5 mL HPLC vial. About 20 μL of the standard and the sample were injected into the HPLC machine separately. The retention time of the peak for albendazole in the sample and the standard were compared for identification since the retention time of the peak for albendazole in the chromatogram of the sample corresponds to that of the standard preparation \[[@CR13]\]. The peak area was used for quantification \[[@CR4], [@CR14]\]. All procedures were done at least three times to increase the precision. System stability was checked prior to running each sample.

Data management and analysis {#Sec3}
============================

The data were checked, coded, and entered into a Microsoft excel work sheet and descriptive statistics were used to summarize the data. The mean, standard deviation, and relative standard deviation (RSD) were used to compare the albendazole standard with different brands. The amount of albendazole in each brand or tablet was calculated by considering the peak area of the sample, the standard, dilution rate and the label claim \[[@CR13]\]. According to USP, an albendazole tablet should contain 90--110% of the labelled amount for acceptable quality \[[@CR13]\].

Results {#Sec4}
=======

All brands of albendazole tablets had uniform shape, size and colour. There were no breakage and cracking of tablets in all brands. Gross contamination was observed in one batch (Table [1](#Tab1){ref-type="table"}).Table 1Physical characteristics of the tabletsProductLabel dose (strength) of API (mg/tablet)Uniformity of shapeUniformity of sizeUniformity of colourBreaks, cracks and splitsSurface spot or contaminationBrand 12500YesYesYesNoNo300YesYesYesNoNoBrand 22500YesYesYesNoNoBrand 32500YesYesYesNoNo600YesYesYesNoYes^a^Brand 4600YesYesYesNoNoBrand 52500YesYesYesNoNo300YesYesYesNoNoBrand 62500YesYesYesNoNo300YesYesYesNoNo^a^ A sample with gross contamination, *API* Active Pharmaceutical Ingredient

The packing information and labelling of the different albendazole brands were assessed based on WHO criteria \[[@CR15]\]. Out of the 6 brands, one (16.7%) brand or two (20%) batches had no leaflet or package insert (Table [2](#Tab2){ref-type="table"}).Table 2Packing information and label for the different brandsProductContainer and closerMedicine strength (mg/tablet)Dosage statementBatch/ Lot NoManufacture and expiry dateStorage informationLeaflet or package insertBrand 1YesYesYesYesYesYesYesYesYesYesYesYesYesYesBrand 2YesYesYesYesYesYesYesBrand 3YesYesYesYesYesYesYesYesYesYesYesYesYesYesBrand 4YesYesYesYesYesYesYesBrand 5YesYesYesYesYesYesNo^a^YesYesYesYesYesYesNo^a^Brand 6YesYesYesYesYesYesYesYesYesYesYesYesYesYes^a^There was no leaflet or package insert

The weight uniformity of albendazole tablets of each brand are presented in Table [3](#Tab3){ref-type="table"}. The study revealed that out of the ten batches, 4(40%) did not comply with the official pharmacopoeial specification limit \[[@CR13]\].Table 3Packing information, expiration date, and weight of different brands of albendazoleProductLabel dose (strength) of API (mg/tablet)Blisters x tabletExpiration dateWeight mg (mean ± SD)\
(*n* = 20)RSDBrand 1250055 (11 × 5)20185950 ± 116.201.9530060 (10 × 6)20191980 ± 69.713.52^a^Brand 2250060 (15 × 4)20196080 ± 55.750.91Brand 3250060 (12 × 5)20204900 ± 201.534.11^a^60060 (5 × 12)20204980 ± 43.020.86Brand 460055 (11 × 5)20194880 ± 60.121.23Brand 5250060 (12 × 5)20195870 ± 56.880.9630060 (10 × 6)20191810 ± 36.632.02^a^Brand 6250060 (12 × 5)20195730 ± 123.192.15^a^30055 (11 × 5)20194830 ± 89.351.85^a^Did not meet the specification for uniformity of weight, *API* Active Pharmaceutical Ingredient, *SD* standard deviation, *RSD* Relative Standard Deviation

Concerning the identification test, all three methods (UVS, FTIR and HPLC) confirmed that all brands passed the identity test, verifying that all samples had albendazole as an active pharmaceutical ingredient (API) in their formulations (Table [4](#Tab4){ref-type="table"}, Figs. [1](#Fig1){ref-type="fig"} and [2](#Fig2){ref-type="fig"}). Fig. [1](#Fig1){ref-type="fig"} depicts that both the sample and the standard have maximum absorbance on the same or equivalent wave length which confirmed that the sample had the intended API. Figure [2](#Fig2){ref-type="fig"} shows the chromatographs of the standard and sample at nearly the same retention time.Table 4Different strengths of the drug that passed the test requirementProductLabel dose (strength) of API (mg/tablet)Identity testBrand 12500Pass300PassBrand 22500PassBrand 32500Pass600PassBrand 4600PassBrand 52500Pass300PassBrand 62500Pass300Pass*API* Active Pharmaceutical IngredientFig. 1Ultraviolet-visible spectra of Albendazole for primary identification test (left-side standard and right-side sample scans, being superimposed)Fig. 2Chromatograph of standard and sample, respectively (upper standard, lower sample)

As it is indicated in Tables [5](#Tab5){ref-type="table"}, [3](#Tab3){ref-type="table"} (50%) brands and 3(30%) batches contained the amount of albendazole which was lower than the acceptable limit. However, the result indicated that there was no drug sample which contained above the acceptable limit.Table 5Percentage (%) and content of brands in mgProductLabel dose (strength) of API (mg/tablet)Label claimed (%)Assay (% mean ± % SD)RSDAssay test\
(90--110%)Brand 1250010094.97 ± 2.572.71Pass30010097.64 ± 0.740.76PassBrand 2250010099.88 ± 0.600.60PassBrand 32500100105.85 ± 9.829.28Pass600100100.82 ± 4.614.57PassBrand 460010087.22^a^ ± 1.571.80FailBrand 5250010094.93 ± 1.801.90Pass30010086.92^a^ ± 1.281.47FailBrand 6250010084.75^a^ ± 0.690.82Fail300100105.73 ± 0.990.93Pass^a^Below 90% (the acceptable range is 90--110%) \[[@CR12]\]; *SD* Standard Deviation, *RSD* Relative Standard Deviation, *API* Active Pharmaceutical Ingredient

Discussion {#Sec5}
==========

For successful therapeutic effect, a pharmaceutical product should contain the appropriate amount of active pharmaceutical ingredient (API) and required physical characteristics. The manufacturer should also provide appropriate information including the product name, amount of API, the indications, contra-indications, warnings, storage information, expiration date, batch number, withdrawal periods, manufacturer name and address, and leaflet insert. In this study, problems were observed with labelling and physical characteristic by gross contamination in one batch and absence of leaflet in one brand (two batches).

Considering the weight per tablet for each brand or batch of a drug is important to assure uniformity of dosage of a drug \[[@CR13]\]. Dosage uniformity helps to ensure a constant dose of drug between individual dosage forms. In this study, assessment of the weight uniformity revealed that four batches did not meet the criteria. In contrast to the finding of this study, absence of variation was reported by Othman \[[@CR16]\] in Yemen. The difference may be related to the manufacturing practices.

According to the official monograph of the USP \[[@CR13]\], the API of a drug should not be less than 90% and greater than 110% of the label claim. If the API of drug is within the acceptance range, the drug can produce the required therapeutic effects with limited side effects on the patient. If the drug contains higher than the expected amount, it may not be safe. On the other hand, if the drug has lower amount of API, it may not cure the animal and my favour the development of anthelmintic drug resistance. There are frequent reports that show resistance to common anthelmintic drugs especially in warm and humid parts of the world \[[@CR17]\].

In this study, out of the ten batches, 3(30%) had less than 90% of the API. This confirmed the presence of sub-therapeutic doses of anthelmintic drugs in the legal market of the country. It is obvious that the occurrence of such a scenario might not cure the patient or favour the development of resistance \[[@CR18], [@CR19]\]. The substandard products could originate from poor preparation techniques during formulation and subsequent manufacturing processes, incorrect weighing and mixing, or it may be intentional to reduce the cost of production \[[@CR20]\]. A relatively high prevalence of poor quality of albendazole was also reported in a separate study by Suleman et al. \[[@CR21]\] in Ethiopia. In Yemen, Othman \[[@CR16]\] assessed the quality of seven brands of albendazole and found that only two brands fulfil the British Pharmacopeia quality control standards. The presence of counterfeit anthelminthic drugs was also reported by Khan et al. \[[@CR8]\] in Cambodia.

Despite some controlling practices in Ethiopia, there are still practices of misuse and smuggling of anthelmintic drugs. In addition, no strategy is in use to preserve and maintain the efficacy of anthelmintic drugs or to delay and prevent the emergence of anthelmintic drug resistance \[[@CR22]\]. The findings of this study raise an alarming concern with regards to suboptimal drugs circulating in the legal market. This can contribute towards several interrelated problems. The implications of these can be: (1) inability to achieve the therapeutic goal which compromises the welfare and productivity of the animals, (2) obligatory repetitive treatments which incur additional costs for the farmer and (3) as a long-term effect, it may increase the presence of resistant parasite population. All of the aforementioned consequences of sub-standard drugs circulating in the legal market may further aggravate the already existing anthelmintic resistance and poor efficacy scenarios reported from different parts of the country \[[@CR2], [@CR7]\]. The clinical significance of drug resistance is highly crucial in notorious parasites like *H. contortus* in which a massive infection can kill the host \[[@CR3], [@CR7], [@CR23]\].

Conclusions {#Sec6}
===========

There were variations in contents of samples of different brands of albendazole. This variation can have significant influence on the drug activity. The presence of low level of API below the official recommended limit often results in treatment failure and favours the development of parasites resistance to the specific anthelmintic drug. Therefore, there should be a strong pre-registration evaluation and regular monitoring of the quality of drugs circulating in the market.
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